Abstract. Combination pairs of the major systematic antimycotic drugs, amphotericin B (AmphB), 5-fluorocytosine (5-FC) and ketoconazole (Ktz) were administered to mice with experimental candidiasis, cryptococcosis and aspergillosis at a variety of combination ratios. The 3 mycoses were produced with 3 strains each of C andida albicans, Cryptococcus neoformans, and Aspergillus fum igatus, respectively, which were preselected to represent 3 different degrees of 5-FC sensitivity ('normally sensitive', 'moderately resistant', and 'definitely resistant'). The life-prolonging effect of the combinations was compared with the effect of each partner administered alone at the same and at the double dosage. Using the U test of Mann and Whitney and setting limits which on the whole were more rigorous than those of the isobole methods commonly applied to the study of drug interactions,
Introduction
In spite of considerable progress made during the last decades, systemic antimycotic chemotherapy still presents a number of problems. This is explained on one hand, by the extreme gravity of many of the mycoses in question and on the other, by the paucity of the available drugs of which each one has its limitation (e.g. side effects, risk of resistance, or poor penetration into certain compartments of the body). Not sur prisingly, there has been an increasing in terest in drug combinations, with the hope that they may offer advantages such as smaller dosage of the partners, reduced in cidence of resistance, and complementary pharmacokinetics of the 2 drugs, particu larly with respect to penetration. Several clinical studies exist indicating that the one or the other of these expectations was ful filled by combining amphotericin B and 5-fluorocytosine, especially in cryptococcal meningitis [4, 21, 38] , Candida endocarditis [39] and invasive aspergillosis [23, 35] , Clinical experience with combinations of the most recent drug, ketoconazole, with any of the older antimycotics is still scarce. However, the results from experiments using combinations of various imidazolyl com pounds (miconazole, econazole or ketoco nazole) with amphotericin B were conflict ing in showing synergism in some models [18, 28] but antagonism in most of the others [10] [11] [12] 33] .
In this paper a comparative study is presented on the chemotherapeutic useful ness of the combinations amphotericin B plus 5-fluorocytosine, amphotericin B plus ketokonazole, and 5-fluorocytosine plus ke toconazole in murine models of candidiasis, cryptococcosis and aspergillosis.
Materials and Methods

Organisms
Candida albicans: strains H12, 13 and 140/1 C ryptococcus neoform ans: strains 1549, 1820 and 1841, Aspergillus fum igatus strains 437, 636 and 638. These strains were preselected according to their sensitivity to 5-fluorocytosine in vitroone strain of each species should represent good (norm al) sensitivity, the second moderate ('par tial') resistance and the third definite resistance to this drug. All these fungi are being kept in our laboratory either deep-frozen or lyophilized in order to preserve the virulence. F or the inocula, fresh subcultures were always taken from the stock.
C om pounds
A m photericin B (AmphB, Squibb, UK), 5-flu orocytosine (5-FC, Roche), ketoconazole (Ktz, Janssen, Beerse, Belgium).
Fungistatic A ctivity o f the Single Compounds in vitro
F o r 5-FC a chem ically defined, liquid culture m edium , yeast nitrogen base (Difco) was used to which 0.5°/o o f dextrose and 2% of agar were added. C asitone agar (containing casitone 9 g, dextrose 20 g, yeast extract 10 g, K H 2 P O 4 1 g. NaaHPCh 1 g, sodium citrate 10 g, agar 20 g/1) was used fo r testing Ktz and AmphB. Yeast cells (C. albicans and C. neof orm ans) or conidia (A. fumigatus) were suspended in the m elted m edia to give a density of 1,000 cells/ml. Using 1:3 dilution steps of each drug the m inim um inhibitory concentra tion (M IC) and the concentration producing definite relative (incomplete) inhibition were deter mined after 3 days of incubation at 37 °C (C. albicans and A. fum igatus) or 30 °C (C. ne0' form ans).
Septic Candidiasis, Aspergillosis and C ry p to co c cosis in the M ouse
The mice used for these experiments were male albinos Fiillinsdorf, weighing a p p r o x i m a t e2 0 g. A ll fungi (yeasts or spores) were injected into a tail vein. The inocula per mouse were as follows. C. albicans strain H12: 3 X 105, strain 140/1: 4 X 10s, and 13: 8 X 105 yeast cells from a 24-hour culture on Sabouraud's dextrose agai at 37 °C ; C. neoform ans strain 1549: 8 X 10 ' The 3 strains o f each species were preselected according to their sensitivity to 5-FC: the First (on the left) should represent good (norm al) sensitivity to this drug, the second (in the m iddle) m oderate sensitivity = 'p ar tial resistance' and the third (on the right) deFmite resistance.
MIC in /ig/m l read after 3 days o f incubation at 37°C (C. albicans and A. fum igatus) or 30°C (C. neofor mans). ! The Figures in parentheses indicate the concentrations in ug/m l producing definite though only partial (relative) inhibition of growth. strain 1820: 3 X 106, and strain 1841: 1 X 106 yeast cells from a 2-to 3-day culture on Sabouraud's dextrose agar at 30 °C ; A . fum igatus strains 437 and 638: 4 X 106, and strain 636: 8 X 106 conidia from a 4-to 5-day culture on S abouraud's dex trose agar at 37 °C. W ith these inocula septic mycoses are regularly produced in untreated con sol animals killing 80-90% w ithin the observation Period of 21 days. The median survival tim e of !he controls is in the order of 6-8 days in can didiasis, 4-5 days in cryptococcosis and 6 days in aspergillosis.
Dosage Schedules
The single and com bined drugs were admmistered 3 times in candidiasis, 5 times in cryp-!°coccosis, and 6 times in aspergillosis. The first these individual doses was given im m ediately a^er the infection, the second and third approximately 6 and 24 h, respectively, thereafter, and fourth and sixth once daily on the subSe<lUent days. Of each drug and drug combinatl0n the dosage was varied using 1:2 steps. In each experiment the num ber of dosage steps USUaHy was 3-4. 10 anim als were used per dosage group, and 10 anim als served as untreated con trols. The route of adm inistration was per os for Ktz, and subcutaneous (s.c.) for 5-FC and AmphB.
C hem otherapeutic A ctivity o f the Single C om pounds
The effective dose 50% (ED50), i.e., the dose keeping alive 50% of the anim als until the end of the observation period, was estim ated graphi cally on probability paper. W hen there were sur vivors in the control group, the percentages of survivors in the treated groups w ere corrected by the form ula:
C orrected percentage = obtained percentage -% surviving controls 100 -% surviving controls
As an additional param eter of effectiveness, the dose producing a 50% prolongation of the m edian survival tim e of the treated anim als com pared with the m edian survival time of the con trols, was calculated. (In the experim ental m y coses in question, a 50% prolongation of the m edian survival time is usually consistent with a p < 0.05 prolongation of the survival times of 4 Doses with the prefix < indicate the lowest dosage used which, however, produced a still stronger effect than is required by the param eter in question. 5 Doses with the prefix > indicate the highest dosage used which was, however, still too low to produce the effect required by the param eter in question.
the individual m ice as determ ined in a rank test.) As dose-effect curves, cubic splines of the per centages were used according to program ICSSCU of the IM SL L ibrary (H ouston, Tex.). F o r the splines the follow ing conditions were stipulated: (i) no change of the sign in the first derivation, and (ii) not m ore than one change of the sign in the second derivation of the spline function. W ithin these conditions the splines w ith the lowest sum of squared deviations w ere chosen.
C om bined C hem otherapy
The com bination experim ents were perform ed w ith any pairs am ong the 3 drugs (i.e., with AmphB + 5-FC, A m phB + K tz , and 5-FC + Ktz), w hereby the 2 partners were adm inistered im m e diately after each other. A variety of combination ratios was used for each pair in the aim to cover the range between sublim inal and p r o n o u n c e d activity of the single partners. Accordingly, the dose of the AmphB com ponent was always much sm aller than the dose of the 5-FC or Ktz com ponents, whereas the doses of the 5-FC and Ktz com ponents were in a sim ilar range. F or example* in the experim ents with C. albicans strain H12. each of the 3 AmphB dosages: 0.063, 0.125 a n d 0.25 mg/kg, was com bined with each of the 5-FC dosages: 6.3, 12.5 and 25 mg/kg, and with each of the 4 Ktz dosages: 6.3, 12.5 25 a n d 50 mg/kg; and each of the 3 5-FC and 4 Ktz dosages just indicated was com bined with e a c h other. The dosages of 5-FC were higher in foe experiments with the C. albicans strains 140/1 a n d 13 and w't'1 C-neoform ans and A. fum igatus s tr a in s , according to the m inor susceptibility of these strains to 5-FC alone. F o r analogous reasons, the dosages of the K tz com ponent were higher in the experim ents w ith the C. neoform ans and, particularly, the A . fum igatus strains (for the detailed dosage groups see tables III-V ). In each e x p e r i m e n t the drugs were tested singly at the same dosages as those used in the com binations, in addition, the single drugs were tested at twice the highest dosage used in com bination to perm it comparison with the activity of the double dosage of each of the single partners. G roups of 10 mice were used for each of the com bination ratios and each of the single partners.
The effect of com bined chem otherapy was classified in one of the 4 categories: 'antagonism ', 'indifference', 'addition' or 'synergism '. This clas sification was m ade as follows:
( With the sam ple sizes in question (2 X 10), 28 and U > 72 reflect a significance level p = 0.10 (one-tailed). This relatively high p Was considered justified, since -due to the re latively small sam ple sizes -the risk of errors of the second kind (failure to detect actual dif ferences) would have been too great with a lower p. F urtherm ore, the higher p seemed justified by the fact that the decisions fo r addition and syn ergism were based on com parisons of the com bina tions with the m ore active of the single partners.
Results
A ctivity o f the Single C om pounds in vitro (table I)
The desideratum that of the 3 strains of each species one each should represent (i) high (normal) sensitivity, (ii) moderate sensitivity = 'partial resistance' and (iii) definite resistance to 5-FC, was met quite well in C. albicans and C. neoform ans. In A . fum igatus one strain (437) w'as normally sensitive but the remaining 2 (636 and 638) were almost indistinguishable with the cri teria used (MIC and definite relative in hibition) and both appeared to lie between 'partial' and definite 5-FC resistance. As expected, sensitivity to AmphB and Ktz was unrelated to the sensitivity to 5-FC. AmphB proved to be most potent in show ing about equally low MICs against all strains of any of the 3 species. Ktz was highly active on the strains of C. neofor mans but moderately active on those of C. albicans and A . fumigatus. (table II) AmphB was the most potent drug by far in that ED50ies -which usually were below 1 mg/kg -were obtained in the in fections with any strains of the 3 species. 1 factions with only one strain each of } three species and were of a higher order (25 mg/kg in the 5-FC case, and 115, 1 5 0 and 200 mg/kg in the Ktz cases). On the other hand, doses producing a 50°/o prolongation of the median survival time were measurable in all instances, includ ing those of the mycoses treated with 5-FC and Ktz. The respective doses were below 0.1 mg/kg with AmphB. whereas with 5-FC and Ktz, they ranged from < 20 up to 200 mg/kg according to the fungus species and to the sensitivity of the par-| ticular strain. In the case of 5-FC the arbi trary differences in the sensitivity of the 3 strains of each species in vitro (see table I ) were still noticeable in vivo but generally less pronounced. (table  HI) . No instance of antagonism was ob- served with any of the combinations (total number of combinations = 89) in any of the infections. The instances of indifference were 41 altogether, but those of addition were almost as many (35) and those of synergism still numerous (13) . However, the instances of enhancement (addition or synergism) were unevenly distributed to the 3 species: they were less numerous in the infections with A . fum igatus than in those with C. albicans and C. neoform ans.
C hem otherapeutic A ctivity o f the Single C om pounds
Effects o f C om bined C hem otherapy Combinations A m p h B + 5-FC
Of the 13 instances of synergism, 11 oc curred in the infections with C. albicans and as many as 7 in those with the single C. albicans strain 13 showing definite re sistance to the 5-FC component in vitro (table I) .
In figure la-f, the percent survivor curves of the mice are shown for 6 individual combinations (designated on the graphs as AB [ = AmphB] + 5-FC) in comparison to those observed with the single drugs administered at the same dos age (designated as AB and 5-FC, respec tively) and at the double dosage (2AB and 2-5-FC). The examples are taken from the infections with 6 different strains (2 each for the 3 species). In figure lc and f, in stances of addition are shown, and in figure la, b, d and e those of synergism. (table IV) . The most impressive findings were, on the one hand, the high incidence of antagonism (28 instances altogether out of a total num ber of 72 combinations), and on the other, the distribution of these instances only to the infections with the 3 strains of A . fu m i gatus and to those with 2 out of the 3 strains of C. albicans, whereas numerous instances of addition (altogether 17) and even several of synergism (6) were observed with the 3rd strain of C. albicans and with all 3 
Com binations A m p h B ± K tz
Discussion
D istinction of Synergism, A ddition, Indifference and A ntagonism
In this paper the interaction of any pair among the 3 systemic antimycotics, AmphB, 5-FC and Ktz, on the 3 murine mycoses candidiasis, cryptococcosis and aspergillosis was studied and was classified as 'synergis tic', 'additive', 'indifferent' or 'antagonis tic'. To produce the 3 mycoses, 3 different strains each were used so that the number of models was 9. The 3 strains of each species were preselected to represent dif ferent degrees of susceptibility to 5-FC ('sensitive', 'partially resistant" and 'defi nitely resistant'), since the possible existence and the prevention of resistance to 5-FC have been major arguments for the use of this drug in combination with another.
For an interaction to appear, and to reach its optimum, a certain proportion of the doses of 2 given antimicrobial drugs is usually required. Not infrequently the opti mum. additive or synergistic proportion is 
---------------------
1 Each effect was evaluated by com paring the survival times o f 10 anim als receiving the particular com bina tion with 10 anim als each receiving the single drugs at the same and at the double dosage (see M aterials and Methods). The 3 strains of each species were preselected according to their sensitivity to 5-FC: the first (on the left) should represent good (norm al) sensitivity to this drug, the second (in the m iddle) m oderate sensitivity = 'p ar tial resistance' and the third (on the right) definite resistance (cf. table I, II). J indiff = indifference; add = additive effect; syn = synergism; ant = antagonism . similar to the proportion of the active doses °f the 2 drugs used alone. It was difficult to apply this rule to the present study, since depending on the parameter of activity, the Proportions of the active doses of the single drugs often varied considerably. For example, for AmphB and 5-FC in the infec tion with C. albicans strain 140/1, it was 260 when comparing the ED50ies, but 1: >1,500 when comparing the doses pro ducing a 50%> prolongation of the survival time. In order to overcome this problem, a great variety of dose levels and dose pro portions was used for each of the combina tions in each of the models (tables III-V). Indeed, no attempt was made to determine the optimum proportions in detail. Most commonly, the additive and syner- gistic effects of 2 antimicrobials are deter mined, and are discriminated from each other, by means of isobolic diagrams [16, 24] , or by similar methods analyzing the contribution made by the fraction of each partner present in the combination, to the total activity of the combination [15] . For antifungal combinations, such methods were, e.g., used by B lock and B ennett [6] , H am il ton and E lliot [19] .
indiff
With the isobole procedures a certain endpoint of activity, e.g., an ED50, is first determined for each one of the drugs alone and for their combination at certain pro portions. At the endpoint level, the fractional doses of each partner present in the com bination are then compared with the doses of the 2 single drugs required with mono therapy, putting the latter doses at 1.0 each. An additive effect is taken for granted if the sum of the fractional doses is 1.0, and synergism, if the sum is less than 1.0. In the usual diagram, the limit is consistent with the 'addition line' combining the 1.0 dose points of the 2 single drugs put on the abscissa and ordinate, respectively. In accordance with this, addition is not only proven for combinations containing half the dose of each component producing the defined endpoint activity, but also for those containing more than half of the 'endpoint dose' of the one of the components, as long as the fractional dose of the other com ponent is small enough to keep the sum at 1.0. In other words, combinations are still considered additive, when the activity in question is produced by less than the double dose of the one of the single partners (which is the more active in this case), pro vided that a correspondingly higher dose is required of the other (less active) partner. A sum of more than 1.0 indicates indif ference, as long as the fractional dose of any of the 2 partners is not greater than 1.0, but antagonism is indicated if any one is greater. In the diagram, the 'line of mdifference' has 2 perpendicular parts con sistent with the parallels put through the 1-0 dose points of the single drugs forming a square with the abscissa and ordinate [16] Commonly, the effects of combinations cor responding to points between the 'addition line' and the 'line of indifference are al-,eady considered to indicate indifference, but strictly speaking th e y indicate undefined 'mixtures' of indifference and addition. By some authors all points beyond the addition line (and all sums greater than 1.0) were c o n sid ered evidence of antagonism [5] , but these were obviously errors [26] . The isobole method can only be applied to pairs of drugs whose dose activity curves have a similar slope [17] . The fact that it does not offer statistical analysis of what is a 'same' and a 'different' effect (does, e.g., a sum of 0.9 of the fractional doses already indicate synergism?) and the some what unclear distinction between addition and indifference are further disadvantages of this method.
With the drugs and disease models studied in this paper, the requirement of similar dose activity curves was not fulfilled. This is re flected by the, often, very different quotients between the ED50ies and the doses pro ducing a 50% prolongation of the survival (table II) . For example, in the infection with C. albicans No. 140/1, this quotient was 2.4 for AmphB but > 16 for 5-FC. On the other hand, the limits we set for additive and synergistic effects were more rigorous than those used in an isobolic diagram, since we only relied on the differences with the more active of the 2 single partners, without takmg into account the contribution made by the other component present in the com bination. Furthermore, the limits for 'same' and 'different' effects were determined sta tistically. (As outlined in Materials and Methods, the U limits generally correspond to p values of less than 0.05 and a clear definition of indifference was used.) With 0ur method, the activities were not comPared at a certain endpoint (e.g., the ED50) evek but a direct comparison was made of the survival pattern of the mice observed with the combinations and single com ponents at the dosages in question. This procedure may have favoured the appear ance of incidental differences at some dos ages as well as the nonappearance of true differences at some others. However, the various classes of interaction (synergism, addition etc.) were far from being distributed at random, but on the contrary were con centrated to certain pairs of drugs and cer tain models (table III-V) . Thus, we believe that the general classification resulting from this study is reliable.
This general classification is presented in table VI for each of the 3 pairs of drugs with respect to each of the 9 disease models (3 each of candidiasis, cryptococcosis and aspergillosis). The degrees of interaction are indicated with the terms 'synergism', 'addi tion' etc. when they were observed with at least 2 of the individual dosages of the combinations (table III-V). The terms are italicized when the degree in question was observed at 5 instances or more.
C om bination A m p h B plus 5-FC
This combination was definitely syner gistic or, at least, definitely additive in candidiasis. It had a definitely additive effect in cryptococcosis, whereas in aspergillosis only weak addition (one model) or indif ference (2 models) was found. In candi diasis and cryptococcosis, the beneficial effect of the combination also extended to the infections with the moderately and de finitely 5-FC-restistant strains of C. albicans and C. neoform ans.
This general picture agrees well with the common experience with these groups of fungi. Since the first report by M ed o ff et al. [25] in 1971, beneficial (additive or syner gistic) antifungal effects of AmphB plus 5-FC on C. albicans and C. neoform ans were widely confirmed in vitro and in animal models of candidiasis and cryptococcosis [for the first observations in vivo, see 6. 13, 36, 37] . They also extended to C. albicans strains 'partially resistant' to 5-FC and even were more pronounced in these [27, 30] . Still beneficial though at best additive effects were later observed with aspergilli in vitro [22] and in vivo [1] , Occasionally, lack of any improvement compared with the effects of the single components was also reported, e.g., in Candida endocarditis in rabbits [7] , cryptococcosis in mice [19] and aspergillus endocarditis in rabbits [27] , and even a certain antagonism was claimed to have occurred in mice infected with a 5-FCresistant strain of C. neoform ans [19] . The latter claim seems doubtful, since as far as we understand, any lack of addition in the isobolic diagram was taken as antagonism by the authors, without considering indif ference.
Combined chemotherapy with AmphB and 5-FC showed advantages over the che motherapy with AmphB alone, or with either AmphB or 5-FC alone, in human CNS cryptococcosis [4, 21, 38] , and this com bination was used successfully also for severe cases of human candidiasis and invasive aspergillosis [see e.g. 8, 9, 14, 35, 39, 40] , although superiority over AmphB alone was not assessed.
AmphB is fully active on 5-FC-resistant mutants, and in C. albicans, the 5-FC re sistance frequency was found to be reduced at subinhibitory concentrations of AmphB [31] . A substantial number of the failures of 5-FC monotherapy in human mycoses (particularly CNS cryptococcosis and asper gillosis) was explained by the emergence of 5-FC resistance [see e.g. 34], whereas sec ondary 5-FC resistance was not or only rarely observed with the combination AmphB plus 5-FC [4, 38] . In most of the animal models used for antifungal chemo therapy including ours, the treatment period was too short for a selection of resistant mutants. (In unpublished experiments using the same treatment schedule is in the pres ent study, we did not find any increase of resistant mutants in the organ cultures from animals dying in spite of 5-FC mono therapy.) Hence, in human chemotherapy, the prevention of secondary 5-FC resistance is a probably major, additional advantage of the AmphB plus 5-FC combination which is not revealed by the usual in vitro and in vivo models.
Com bination A m p h B plus K tz
The marked differences in the interaction we observed with this combination from one model to another, were striking: Where as the effect was definitely beneficial (mostly additive) in the infections with the 3 strains of C. neoform ans, antagonism throughout occurred in the infections with the 3 A . fum igatus strains. Most surprisingly, def inite antagonism was found in 2 of the candidiasis models (infections with the C. albicans strain H I 2 and 140/1), but synergism in the third (infection with C. albicans strain 13).
The published experience with the AmphB plus Ktz combination known to us is limited to C. neoform ans and H . capsulatum. An additive effect on these fungi was found in vitro, but in murine infections the combination was not better than AmphB alone (cryptococcosis) or Ktz alone (histo plasmosis); on the other hand, in the crypto coccosis model, the combination AmphB plus Ktz resulted in longer survival of the mice than the combination AmphB plus 5-FC [18] . Superior activity of the com bination AmphB plus Ktz over each of the single partners was found in a rabbit model of cryptococcal meningitis [28] , Antagonistic effects on yeasts of the C a n d id a group (mostly, C. albicans) in vitro were repeatedly observed when AmphB was combined with the imidazolyl antifungals miconazole [10, 12, 33] , econazole [11] and clotrimazole [10] , whereas a beneficial (additive) effect on such fungi was, to our knowledge, recorded only once for the combination AmphB plus clotrimazole [2] , On C. neoform ans (22 strains) the com bination of AmphB with miconazole or econazole had an antagonistic effect in vitro [12] , The antagonism in the antifungal action of the imidazolyls on the one hand, and AmphB on the other was explained by the different role they play on the ergosterol in the membrane of the fungi: Whereas the imidazolyls inhibit ergosterol biosynthesis, AmphB must bind to ergosterol in order to act; by the action of the imidazolyls AmphB would lose its substrate [29] , No published experience is obviously available on the effect of combinations of AmphB with the various imidazolyl antifungals on in vivo Models of candidiasis or cryptococcosis (exCept for the before-mentioned, favourable results with AmphB + Ktz in experimental cryptococcosis), and no report was found on lhe effects on aspergilli either in vitro or in vivo.
Combination 5-FC plus K tz
With our murine models, an additive to Moderately synergistic effect was consisten% found in candidiasis (the, relatively, m°st pronounced synergism occurred in the infection with the definitely 5-FC-resistant strain of C. albicans), whereas on crypto coccosis and aspergillosis, there was neither a positive nor a negative interaction of the 2 drugs.
There are a few published reports on experiments with combinations of 5-FC and Ktz or other imidazolyl antifungals. In vitro, the combinations of 5-FC plus Ktz, 5-FC plus miconazole and 5-FC plus econazole were indifferent (neither additive nor syner gistic) when tested on C. albicans strains fully sensitive to 5-FC, but on strains which were 5-FC-resistant at any degree, the action of all these combinations was syner gistic [32] , Beneficial (mostly additive) effects on yeast-like fungi were observed with the combinations 5-FC plus Ktz (C. albicans including 5-FC-resistant mu tants, C. tropicalis, C. parapsilosis, T. glabrata [3] ), 5-FC plus clotrimazole (candida group [2] ; C. neoform ans [20] , and 5-FC plus miconazole or econazole), C. albicans C. neoform ans [12] ). The beneficial in vivo effect of the 5-FC plus Ktz combination on murine candidiasis described in the present paper was mentioned by one of us (A .P .) in an earlier study in which the combinations 5-FC plus miconazole and 5-FC plus econa zole were found to be indifferent (neither additive nor antagonistic) in the same disease models [32] , In murine cryptococcosis, the combination 5-FC plus Ktz was found in different [18] , whereas a beneficial effect was observed with 5-FC plus clotrimazole [20] .
Very recently, the successful treatment of 2 human cases of pulmonary aspergillosis with a combination of 5-FC plus Ktz was reported. In both cases, there was some evidence that this combination was more effective than other drugs alone, including Ktz [23] . As AmphB, Ktz is fully active against 5-FC-resistant mutants. As mention ed before, combinations with 5-FC wich are 'indifferent' in our animal models may well be 'synergistic' in certain human mycoses thanks to the prevention of secondary 5-FC resistance.
